Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02172326
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : June 24, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to evaluate the pharmacokinetics of tiotropium following 14 days of administration (18µg once per day) in elderly COPD patients.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: Tiotropium inhalation capsules for oral inhalation Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Pharmacokinetics, Safety and Tolerability of Tiotropium in Elderly COPD Patients (Open Label, Monocenter Study).
Study Start Date : February 1998
Actual Primary Completion Date : September 1998

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tiotropium inhalation capsules Drug: Tiotropium inhalation capsules for oral inhalation
Powder inhalation via HandiHaler®

Primary Outcome Measures :
  1. Total area under the plasma drug concentration-time curve (AUC 0-4 h) [ Time Frame: pre-dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14 ]
  2. Urinary excretion of tiotropium (Ae(0-4 hours)) [ Time Frame: screening and on days 1, 7, 14, 15, 16, 20, 24, 28, 31, 35, 38 ]
  3. Renal clearance of tiotropium (CLren) [ Time Frame: screening and on days 1, 7, 14, 15, 16, 20, 24, 28, 31, 35, 38 ]
  4. Terminal elimination half-life after the last dose [ Time Frame: pre dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14 ]

Secondary Outcome Measures :
  1. Plasma concentration of drug 5 min after inhalation (C5min) [ Time Frame: pre dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14 ]
  2. tmax (time of occurrence for maximum drug concentration) [ Time Frame: pre dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14 ]
  3. Change from baseline in FEV1 (Forced expiratory volume in one second) [ Time Frame: Baseline, Days 1, 7 and 14 ]
  4. Change from baseline in FVC (Forced vital capacity) [ Time Frame: Baseline, Days 1, 7 and 14 ]
  5. FEV1/FVC [ Time Frame: Baseline, Days 1, 7 and 14 ]
  6. Symptom evaluation [ Time Frame: 2 weeks ]
  7. Use of salbutamol [ Time Frame: 2 weeks ]
  8. Occurrence of Adverse Events [ Time Frame: up to day 39 ]
  9. Occurrence of Adverse Events [ Time Frame: up to day 38 ]
  10. Changes form baseline in vital signs (pulse rate and blood pressure) [ Time Frame: up to day 38 ]
  11. Changes from baseline in laboratory tests (haematology, clinical chemistry and urinalysis) [ Time Frame: baseline, day 38 ]
  12. Changes from baseline in physical examination [ Time Frame: baseline, day 38 ]
  13. Changes from baseline in ECG (Electrocardiogram) [ Time Frame: baseline, day 1, 7, 14 and 38 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients were required to have a diagnosis of COPD and to meet the following spirometric criteria:

    • Relatively stable, moderate to severe airway obstruction with an FEV1 ≤ 65% of predicted normal and FEV1/FVC ≤ 70%
  • Patients were required to have normal renal clearance. Renal clearance will be evaluated by the determination of creatinine clearance. To qualify for this trial, the patient's measured creatinine clearance was required to be within 20% of the calculated creatinine clearance, as given by the following equations:

    • Males: Calculated Creatinine Clearance (ml/min) = [140 - Age (yrs)] x weight(kg) / 72 x serum creatinine (mg/dL)
    • Females: Calculated Creatinine Clearance (ml/min) = [140 - Age (yrs)] x weight (kg) / 85 x serum creatinine (mg/dL)
  • Both male or female patients were eligible. Twelve patients ≥ 70 years old and twelve patients ≤ 50 years
  • Patients were required to have a smoking history of more than ten pack-years, where a pack-year was defined as the equivalent of smoking one pack of cigarettes per day for a year
  • Patients must be able to perform all specified procedures and maintain records during the study period as required in the protocol
  • Patients were required to be able to inhale medication from the HandiHaler®
  • Patients were required to sign an Informed Consent Form prior to participation in the trial, including any necessary prior to pre-study washout of their usual pulmonary medications

Exclusion Criteria:

  • Patients with significant diseases other than COPD were excluded from participation in the trial. A significant disease was defined as a disease which in the opinion of the investigator may either have put the patient at risk because of participation in the trial or a disease which may have influenced the results of the trial or the patient's ability to participate in the trial;
  • Patients with clinically significant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defined a disease listed as an exclusion criterion;
  • Patients with alanine transaminase (ALT/SGOT) > 80 IU/L or aspartate transaminase (AST/SGPT) > 80 IU/L, or bilirubin > 2.0 mg/dL or creatinine > 2.0 mg/dL were excluded from participation in the trial, regardless of the patient's clinical condition. Repeat laboratory evaluations were not conducted in these patients;
  • Patients with a recent history (i.e., one year or less) of myocardial infarction (MI);
  • Patients with a recent history (i.e., three years or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy;
  • Patients with regular use of daytime oxygen therapy;
  • Patients with known active tuberculosis;
  • Patients with a history of cancer within the last five years. However, patients with treated basal cell carcinoma are allowed to participate;
  • Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis;
  • Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of a thoracotomy for other reasons were evaluated as per exclusion criterion # 1;
  • Patients who had developed an upper respiratory tract infection in six weeks prior to the Screening Visit (Visit 1) or during the baseline period;
  • Patients with known hypersensitivity to anticholinergic drugs, lactose or any other components of the inhalation capsule delivery system;
  • Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction;
  • Patients with known narrow-angle glaucoma;
  • Patients treated with cromolyn sodium or nedocromil sodium;
  • Patients treated with antihistamines (H1 receptor antagonists);
  • Patients using oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day (or 20 mg every other day);
  • Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm or Norplant®);
  • Patients with a history of asthma, allergic rhinitis or atopy or patients with a total blood eosinophil count ≥ 600/mm3. A repeat eosinophil count was not conducted in these patients;
  • Patients with history and/or active alcohol or drug abuse.
  • Patients who had taken an investigational drug within one month or six half lives (whichever was greater) prior to Screening Visit (Visit 1).

Responsible Party: Boehringer Ingelheim Identifier: NCT02172326     History of Changes
Other Study ID Numbers: 205.133
First Posted: June 24, 2014    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Lung Diseases
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action